JP Morgan Chase’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,017,418
| Closed | -$72.1M | – | 6836 |
|
|
2021
Q1 | $72.1M | Buy |
3,017,418
+2,986,014
| +9,508% | +$55.5M | 0.01% | 1002 |
|
|
2020
Q4 | $458K | Buy |
31,404
+5,443
| +21% | +$72.1K | ﹤0.01% | 4420 |
|
|
2020
Q3 | $363K | Buy |
25,961
+1,443
| +6% | +$22.1K | ﹤0.01% | 4121 |
|
|
2020
Q2 | $360K | Buy |
24,518
+6,322
| +35% | +$64.2K | ﹤0.01% | 3993 |
|
|
2020
Q1 | $75K | Sell |
18,196
-870,394
| -98% | -$4.08M | ﹤0.01% | 4608 |
|
|
2019
Q4 | $4.27M | Sell |
888,590
-113,584
| -11% | -$627K | ﹤0.01% | 2805 |
|
|
2019
Q3 | $6.07M | Sell |
1,002,174
-265,453
| -21% | -$1.66M | ﹤0.01% | 2528 |
|
|
2019
Q2 | $8.06M | Sell |
1,267,627
-1,037,689
| -45% | -$7.31M | ﹤0.01% | 2272 |
|
|
2019
Q1 | $16.3M | Sell |
2,305,316
-1,471,519
| -39% | -$9.69M | ﹤0.01% | 1679 |
|
|
2018
Q4 | $18.4M | Sell |
3,776,835
-637,979
| -14% | -$3.32M | ﹤0.01% | 1548 |
|
|
2018
Q3 | $32.4M | Buy |
4,414,814
+36,100
| +0.8% | +$265K | 0.01% | 1292 |
|
|
2018
Q2 | $27.9M | Sell |
4,378,714
-525,543
| -11% | -$3.47M | 0.01% | 1349 |
|
|
2018
Q1 | $26.7M | Buy |
4,904,257
+131,504
| +3% | +$654K | 0.01% | 1317 |
|
|
2017
Q4 | $19.9M | Buy |
4,772,753
+375,813
| +9% | +$2.26M | ﹤0.01% | 1572 |
|
|
2017
Q3 | $41.3M | Buy |
4,396,940
+299,173
| +7% | +$3.11M | 0.01% | 1044 |
|
|
2017
Q2 | $48.5M | Buy |
4,097,767
+559,629
| +16% | +$7.15M | 0.01% | 921 |
|
|
2017
Q1 | $45.4M | Buy |
3,538,138
+170,977
| +5% | +$2.06M | 0.01% | 981 |
|
|
2016
Q4 | $41.2M | Sell |
3,367,161
-20,624
| -0.6% | -$245K | 0.01% | 1005 |
|
|
2016
Q3 | $40M | Buy |
3,387,785
+373,526
| +12% | +$3.61M | 0.01% | 938 |
|
|
2016
Q2 | $26.2M | Sell |
3,014,259
-48,078
| -2% | -$330K | 0.01% | 1209 |
|
|
2016
Q1 | $16.1M | Sell |
3,062,337
-203,137
| -6% | -$1.13M | ﹤0.01% | 1475 |
|
|
2015
Q4 | $25.3M | Buy |
3,265,474
+331,942
| +11% | +$2.55M | 0.01% | 1176 |
|
|
2015
Q3 | $23.1M | Sell |
2,933,532
-875,679
| -23% | -$8.1M | 0.01% | 1176 |
|
|
2015
Q2 | $34.5M | Buy |
3,809,211
+175,371
| +5% | +$1.77M | 0.01% | 1071 |
|
|
2015
Q1 | $47.2M | Sell |
3,633,840
-36,457
| -1% | -$477K | 0.01% | 932 |
|
|
2014
Q4 | $50M | Buy |
3,670,297
+407,745
| +12% | +$4.56M | 0.01% | 932 |
|
|
2014
Q3 | $29.3M | Buy |
3,262,552
+221,415
| +7% | +$2.38M | 0.01% | 1212 |
|
|
2014
Q2 | $41.1M | Sell |
3,041,137
-343,136
| -10% | -$3.58M | 0.01% | 951 |
|
|
2014
Q1 | $33.6M | Buy |
3,384,273
+831,753
| +33% | +$10.3M | 0.01% | 1022 |
|
|
2013
Q4 | $33.9M | Buy |
2,552,520
+462,403
| +22% | +$5.62M | 0.01% | 1010 |
|
|
2013
Q3 | $25.4M | Buy |
2,090,117
+1,732,962
| +485% | +$18.6M | 0.01% | 1161 |
|
|
2013
Q2 | $3.7M | Buy |
+357,155
| New | +$4.92M | ﹤0.01% | 2351 |
|
JP Morgan Chase's GNMK Position: Q2 2021 in Review
JP Morgan Chase sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 3,017,418 shares — an estimated $72.1M sold.
JP Morgan Chase first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $72.1M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- JP Morgan Chase reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- JP Morgan Chase sold 3,017,418 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $72.1M.
- JP Morgan Chase first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- JP Morgan Chase's GenMark Diagnostics, Inc position peaked at $72.1M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.